Hemlibra (Emicizumab-kxwh) for Hemophilia | MyHemophiliaTeam

Connect with others who understand.

sign up Log in
About MyHemophiliaTeam
Powered By

Hemlibra is approved by the Food and Drug Administration (FDA) as routine prophylaxis in children and adults with hemophilia A and factor VIII inhibitors. The technical name of Hemlibra is Emicizumab-kxwh.

Hemlibra is a biologic drug - a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Hemlibra is believed to work by connecting factors IXa and X, proteins that, when brought together, activate the coagulation cascade process and allow blood to clot.

How do I take it?
Prescribing information states that Hemlibra is given as a subcutaneous injection once weekly.

Hemlibra comes in the form of a single-use vial.

Side effects
The FDA-approved label for Hemlibra lists common side effects including headache, joint pain, and injection site reactions.

Rare but serious side effects listed for Hemlibra include thrombotic microangiopathy and thromboembolism, conditions in which potentially fatal blood clots form.

For more details about this treatment, visit:

Hemlibra - Genentech

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in